ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1364 • ACR Convergence 2025

    Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial

    Prativa Priyadarshani Sethi1, Venkatesh Srinivasa Pai2, Rajat Ranka2, Avneet Kumar Gupta3, Ashish Baweja4, ritu sangwan5, Abhishek Rai6, Sryla Punjadath1 and Nithya Maskani2, 1All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, 2AIIMS RISHIKESH, Rishikesh, Uttarakhand, India, 3AIIMS RISHIKESH, Lucknow, Uttar Pradesh, India, 4Medanta, The Medicity, Gurugram, New Delhi, Delhi, India, 5AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, 6AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India

    Background/Purpose: Early rheumatoid arthritis (RA) is a critical therapeutic window where prompt treatment targeting remission or low disease activity can significantly reduce long-term disability and…
  • Abstract Number: 1345 • ACR Convergence 2025

    Upregulated TLR Signaling Identified in Difficult-to-Treat RA: A Propensity Score–Matched Transcriptome Study

    YOSHINORI NISHIURA1, YOSHIHARU SATO2, YU NAKAI1, MOE TOKUNAGA1, KENTA SHIDAHARA1 and YOSHINOBU KOYAMA3, 1Japan Red Cross Okayama Hospital, Okayama-shi, Okayama, Japan, 2DNA Chip Research Inc., Kawasaki-shi, Kanagawa, Japan, 3Japanese Red Cross Okayama Hospital, Okayama, Okayama, Japan

    Background/Purpose: Difficult-to-treat rheumatoid arthritis (D2T-RA) represents a clinically challenging RA subset defined by failure to achieve disease control despite multiple conventional and advanced therapies. The…
  • Abstract Number: 1329 • ACR Convergence 2025

    Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis

    Carolina Ramirez-Becerra1, Tulsi Joishy2, Sheau-Chiann Chen2, Marisol Ramirez-Solano2, Quanhu Sheng2, Peter Turnbaugh3, Carles Ubeda4, Renuka Nayak5, Rebecca Blank6, Jose Scher7 and Michelle Ormseth2, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University Medical Center, Nashville, 3University of California, San Francisco, San Francisco, CA, 4Fisabio, Madrid, 5University of California, San Francisco (UCSF), San Francisco, CA, 6NYU Langone Health, New York, NY, 7New York University School of Medicine, New York, NY

    Background/Purpose: Microbiome and microbial products are possible contributors and predictors to methotrexate (MTX) response variability. Bacterial small RNAs (sRNAs) are found in human plasma and…
  • Abstract Number: 1313 • ACR Convergence 2025

    Retrospective Analysis of Factors Associated With Fracture in 2855 Patients With Rheumatoid Arthritis, Stratified by Steroid Use

    Jonathan Barnes1, Hamzah Amin2 and marwan Bukhari3, 1Morecambe Bay NHS Trust, Lancaster, United Kingdom, 2Lancaster University, Lancaster, United Kingdom, 3University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom

    Background/Purpose: Steroids are used in a proportion of patients with rheumatoid arthritis (RA). Steroids are known to cause a decrease in bone mineral density (BMD),…
  • Abstract Number: 1225 • ACR Convergence 2025

    Association between Anxiety and Tender Swollen Joint Difference in Patients with Rheumatoid Arthritis

    Clarice Lin1, Burcu Aydemir2, Jing Song3, Lutfiyya muhammad2, Clifton Bingham4, Tuhina Neogi5, Wendy Marder6, Marcy Bolster7, Daniel Clauw8, Dorothy Dunlop9 and Yvonne Lee1, 1Northwestern University, Chicago, IL, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3Northwestern University Feinberg School of Medicine, Worthington, MN, 4Johns Hopkins University, Baltimore, MD, 5Boston University School of Medicine, Boston, MA, 6University of Michigan, Ann Arbor, MI, 7Massachusetts General Hospital, Concord, MA, 8Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, 9Northwestern University Feinberg School of Medicine, Chicago

    Background/Purpose: Some patients with rheumatoid arthritis (RA) have pain, despite normalization of inflammatory markers and reduced swollen joint counts. Among these patients, the number of…
  • Abstract Number: 1055 • ACR Convergence 2025

    The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use

    Antara Dattagupta1, Colin Diffie2 and Sana Cheema2, 1Washington University in St. Louis, St. Louis, MO, 2Washington University in St. Louis, St. Louis

    Background/Purpose: High-cost biologic therapies are integral to the management of rheumatoid arthritis (RA), yet access to these agents may be influenced by insurance type, particularly…
  • Abstract Number: 0996 • ACR Convergence 2025

    Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation

    Obinna Ubah, Euan Murray, Stella Priyanka, Julia Martinez Fraile, Andrew Porter, Robert Boyd and Caroline Barelle, Elasmogen Limited, Aberdeen, United Kingdom

    Background/Purpose: Despite advances in therapies for chronic autoimmune diseases such as rheumatoid arthritis (RA), significant unmet needs persist, including therapeutic ceiling effects, adverse events, and…
  • Abstract Number: 0890 • ACR Convergence 2025

    Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways

    Julia Nicole Zeid1, Kaitlyn Arce2, Nanxi Guo1, Kartik Bhamidipati3, Kevin Wei4, Larry Moreland5, Fan Zhang6 and Anna Helena Jonsson2, 1University of Colorado School of Medicine, Aurora, 2University of Colorado School of Medicine, Aurora, CO, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 5University of Colorado, Denver, CO, 6The University of Colorado, Aurora, CO

    Background/Purpose: Granzyme K (GZMK)-expressing CD8 T cells have recently been detected in tissues from an increasing number of autoimmune conditions, but their role in disease…
  • Abstract Number: 0814 • ACR Convergence 2025

    Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes

    Annie Brink1, Johan Karlsson Wallman2, Jon T Einarsson1, Meliha Kapetanovic1, Elisabeth Mogard1, Elisabet Lindqvist1, Carmen Roseman1, Kristina Lend3, Merete Hetland4, Mikkel Ostergaard5, Kim Horslev-Petersen6, Dan Nordstrom7, Tuulikki Sokka-isler8, Bjorn Gudbjornsson9, Gerður María Gröndal9, Marte Heiberg10, Espen Haavardsholm10, Michael Nurmohamed11, Anna Rudin12, Ronald van Vollenhoven13, Till Uhlig10, Jon Lampa14 and Tor Olofsson2, 1Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, 2Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, 3Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam; Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, 4Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, 5Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, 6Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, 7Division of Rheumatology, Helsinki University Hospital, Helsinki, Finland, 8Department of Medicine and University of Eastern Finland, Jyväskylä Central Hospital, Juväskylä, Finland, 9Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 10Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 11Amsterdam Rheumatology and Immunology Center, Reade; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands, 12Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, 13Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, 14Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Emerging data indicate an uncoupling between pain and inflammation during the RA disease course, and comorbid fibromyalgia – thought to stem from central pain…
  • Abstract Number: 0500 • ACR Convergence 2025

    Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers

    Sama Hajizadeh1, Tarun Sharma1, Peri Newman2, Julio Hernandez2, Rayford June3, Erik Lehman2, Nicole Wilson1, Nancy Olsen4 and Sharon Banks5, 1Allegheny Health Network, Pittsburgh, PA, 2Penn State Health/ Penn State College of Medicine, Hershey, PA, 3Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, 4Penn State University/Milton S Hershey, Hershey, PA, 5Penn State Milton S. Hershey Medical Center, Hershey, PA

    Background/Purpose: In our previous Rheumatoid Arthritis Medication TAPering (RheumTAP) cohort study of patients with stable RA in remission on biologics +/- methotrexate at Allegheny Health…
  • Abstract Number: 0482 • ACR Convergence 2025

    R-2487, a Synthetic Biology-Based Oral Immunotherapy, Promotes Treg-Mediated Immune Rebalancing and Reduces Disease Activity in Rheumatoid Arthritis Patients

    Christian Furlan Freguia1, Janet Stephens1, Sathya Janardhanan1, Chuck Bourne1, Kaitlyn Skeie1, Hudson Lowe1, David Pascual2 and Gary Fanger1, 1Rise Therapeutics, Rockville, MD, 2University of Wyoming, Laramie, WY

    Background/Purpose: R-2487 is a novel, orally delivered, synthetic biology-based immunotherapy that utilizes Lactococcus lactis as a carrier vehicle to deliver Colonization Factor Antigen I (CFA/I)…
  • Abstract Number: 0466 • ACR Convergence 2025

    Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects

    Tulsi Joishy1, Anastasiia Phothisane2, Phicharmon Kulapatana2 and Michelle Ormseth1, 1Vanderbilt University Medical Center, Nashville, 2Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease that is thought to originate at the mucosa. Despite the mucosa’s importance, few studies have examined…
  • Abstract Number: 0449 • ACR Convergence 2025

    Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life

    Joel Kremer1, Kevin Kane2, George Reed3 and Michael Weinblatt4, 1The Corrona Research Foundation, Delray Beach, FL, 2U of Mass Medical School, Worcester, MA, MA, 3University of Massachusetts Chan Medical School, Worcester, MA, 4Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Low disease activity has been identified as a treatment goal for the treatment of RA. A singlecenter RA registry (BRASS) reported a difference in…
  • Abstract Number: 0432 • ACR Convergence 2025

    Frequency and Characteristics of Ophthalmologic Involvement in Patients with Rheumatoid Arthritis

    Javier Federico Flores Trejo1, Joan Manuel Dapeña2, Florencia Micaela Pascual3, Graciela Liliana Ghiglione1, Juan Manuel Bande3, María Alejandra Medina3, José Angel Caracciolo3 and Silvia Beatriz Papasidero3, 1Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 2Sanatorio Dr Julio Méndez, CABA, Ciudad Autonoma de Buenos Aires, Argentina, 3Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that primarily affects synovial joints but may also involve extra-articular organs. Ocular involvement is one…
  • Abstract Number: 0259 • ACR Convergence 2025

    Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design

    Kristin Highland1, Colin Reisner2, Allison Trucillo3, Deepthi Nair4, Felix Woodhead4, Howard Lazarus4, Craig Conoscenti4 and Martin Kolb5, 1Cleveland Clinic, Shaker Heights, OH, 2DevPro Biopharma, Basking Ridge, NJ, 3Avalyn Pharma, Austin, TX, 4Avalyn Pharma, Cambridge, MA, 5McMaster University, Hamilton, ON, Canada

    Background/Purpose: Progressive Pulmonary Fibrosis (PPF) is an increasingly recognized condition, defined in 2022 to address the progression of pulmonary fibrosis in patients with interstitial lung…
  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology